Acutus Medical Inc (AFIB) Annual Income Statement (USD)
AFIB Quarterly Financials (USD)
Frequently Asked Questions About Acutus Medical Inc (AFIB) Stock
Acutus Medical Inc's (AFIB) last reported annual revenue was USD 7.16 Million.
Acutus Medical Inc's (AFIB) annual revenue growth rate based on the revenue reported in the past 5 years is : 27.03%
Acutus Medical Inc's(AFIB) is not profitable as of its last reported annual financials.
The net profit margin for Acutus Medical Inc's(AFIB) from its laster reported year is -1139.91%
The return on equity (ROE) for Acutus Medical Inc's(AFIB) from its last reported annual financials is : -29.91%
The return on assets (ROA) for Acutus Medical Inc's(AFIB) from its last reported annual financials is : -13.93%
The return on invested capital (ROIC) for Acutus Medical Inc's(AFIB) from its last reported annual financials is : -20.16%
The Debt to Equity ratio for Acutus Medical Inc's(AFIB) from its last reported annual financials is : -3714.90%
The dividend yield for Acutus Medical Inc's(AFIB) from its laster reported year is 0.00%
Acutus Medical Inc's(AFIB) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AFIB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
